Mr. Zeeshan Saeed reports

QUANTUM BIOPHARMA PROVIDES CORPORATE UPDATE

Quantum Biopharma Ltd. has provided the following corporate update. The company has granted 35,000 stock options to certain employees and consultants. Each option granted vests immediately and is exercisable at a price of $6.50 for a period of five years from the issue date. The stock options and the common shares underlying the stock options are subject to a statutory four-month-and-one-day hold period. All stock options were granted in accordance with the company's stock option plan reapproved by shareholders at the company's annual general and special meeting held on May 19, 2023.

About Quantum Biopharma Ltd.

Quantum Biopharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum Biopharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum Biopharma invented Unbuzzd and spun out its over-the-counter version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum Biopharma retains ownership of 19.84 per cent (as of Dec. 31, 2025) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7 per cent of sales from Unbuzzd until payments to Quantum Biopharma total $250-million. Once $250-million is reached, the royalty drops to 3 per cent in perpetuity. Quantum Biopharma retains 100 per cent of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

We seek Safe Harbor.